Why COMPASS Pathways plc (CMPS) Draws Both Optimism and Caution

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of the analysts covering the stock. With a target price range of $8 to $40, the median price target of $15 translates to an upside potential of 119.14% from the current price.

On December 17, Gavin Clark-Gartner, an analyst at Evercore ISI, reaffirmed a ‘Hold’ rating on COMPASS Pathways plc (NASDAQ:CMPS), keeping a price target of $8. This reflects an upside potential of 16.87% from the current level.

Geo Group (GEO) Falls 11.46% on Lower Earnings Outlook

Photo by Anthony Tran on Unsplash

Earlier, on December 9, Oppenheimer upgraded COMPASS Pathways plc (NASDAQ:CMPS) to Outperform from Perform, with a price target of $15. This revision is driven by the prospects of the company’s psilocybin therapy for treatment-resistant depression. The firm believes that the company’s psilocybin-based therapy, COMP360, is well-positioned to lead the transformation of psychedelic medicine in neuropsychiatry.

Oppenheimer sees a record sales opportunity of nearly $1.5 billion for the treatment, which appears substantial considering the company’s current market capitalization of over $600 million. The research firm also noted that COMPASS Pathways plc (NASDAQ:CMPS) is poised to advance beyond key upcoming catalysts, given its strong financial footing with an adequate cash runway, and expects it to benefit from an early-mover advantage in the psychedelics space.

COMPASS Pathways plc (NASDAQ:CMPS) is a London-based biotechnology company emphasizing mental health. Founded in 2020, the company is committed to mental well-being.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.